Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Focus Universal Q2 net loss widens to $1,518,958; revenue rises to $675,170

Focus Universal Q2 net loss widens to $1,518,958; revenue rises to $675,170

ReutersReuters2026/08/14 17:55
  • Focus Universal posted revenue of $675,170 for the three months ended June 30, 2026, up from $35,330 a year earlier.
  • Net loss widened to $1.52 million from $1.51 million in the prior-year quarter.
  • Rental revenue was $651,950 versus no rental revenue a year earlier, following the April acquisition of a Class A office property.
  • Operating expenses climbed to $2.22 million from $1.58 million, driven by $259,663 of property operating expense and $201,024 of depreciation and amortization.
  • Executed leases cover 91,366 square feet through Dec. 31, 2026 across 12 tenants, with $1.46 million of anticipated rental revenue through year-end.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Focus Universal Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-006446), on August 14, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well

Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.

智通财经2026/09/07 07:31
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well